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Monocyte/macrophage response to 2-microglobuIin modified with
advanced glycation end products. We recently found that acidic 132-
microglobulin (132m), a major isoform of 132m in amyloid fibrils of patients
with dialysis-related amyloidosis (DRA), contained early Amadori prod-
ucts and advanced glycation end products (AGEs) formed nonenzymati-
cally between sugar and protein. Further analysis revealed that acidic f32m
induces monocyte chemotaxis and macrophage secretion of bone-resorb-
ing cytokines, suggesting the involvement of acidic f32m in the pathogen-
esis of DRA. Acidic f32m, however, is a mixture of heterogeneous
molecular adducts due to various types of modification. In the present
study, we investigated the modification responsible for the biological
activity of acidic 132m toward monocytes/macrophages. The presence of a
fair amount of 132m species with deamidation was detected in acidic f32m
isolated from urine of non-diabetic long-term hemodialysis patients, but
deamidated 132m had no biological activity. In contrast, normal J32m
acquired the activity upon incubation with glucose in Vitro. Among the
glycated f32m, the pigmented and fluorescent 132m that formed after a long
incubation period, that is, AGE-modified J32m, exhibited biological activ-
ity, whereas 132m modified with Amadori products, major Maillard prod-
ucts in acidic f32m, had no such activity. These findings suggest that AGEs,
although only a minor constituent of acidic 132m, are responsible for
monocyte chemotaxis and macrophage secretion of cytokines, implicating
the contribution of AGEs to bone and joint destruction in DRA.
Dialysis-related amyloidosis (DRA) is a serious complication
recognized with high frequency among long-term hemodialysis
patients [11. Amyloid deposits are mainly located in joint struc-
tures especially in periarticular bones, leading to hemodialysis
arthropathy [1]. The incidence of DRA increases with the age of
the patient and the duration of hemodialysis [2, 3]. /32-micro-
globulin (132m) is a major constituent forming amyloid fibrils in
DRA [4, 5]. Recently, we found [6] that electrophoretically acidic
f32m is an exclusive isoform of /32m forming amyloid fibrils in
patients with DRA. The acidic isoform of 132m was also shown to
exist as a small fraction (—10%) of 132m in the serum and urine of
long-term hemodialysis patients [6]. Physicochemical and immu-
nochemical analyses revealed that acidic 132m obtained from the
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serum, urine, and amyloid fibrils contained the 132m modified with
the Maillard products [6].
Maillard reaction occurs nonenzymatically between sugar aIde-
hyde groups and protein amino groups to reversibly form Schiff
bases, and upon rearrangement, convert into more stable Ama-
don products [N-(1-deoxyfructosyl)derivatives] [7, 81. Then, over
months, some Amadori products are further converted into the
advanced glycation end products (AGEs), through a series of
chemical rearrangement, dehydration, and fragmentation reac-
tions. AGEs constitute a heterogeneous class of structures that
are brown in color, fluoresce, and tend to polymerize and cross
link [7, 8]. In fact, acidic f32m purified from urine of long-term
hemodialysis patients contained both Amadori products and
AGEs [6, 9]. Our further study showed that a significant amount
of pentosidine, a fluorescent cross-linked molecule and a glycoxi-
dation marker for AGEs [10, 11], is present in acidic /32m obtained
from the urine and amyloid fibrils at almost equivalent amounts,
indicating that pentosidine is one of the native AGE-structures in
132m in DRA (unpublished data).
Since AGEs can initiate a variety of biological effects mediated
by receptors/cell-surface binding proteins on monocytes/macro-
phages [12—14], we previously investigated the effect of acidic 2m
on monocytes/macrophages to assess the possible involvement of
AGE-modified f32m in bone and joint destruction of DRA. In
these studies, because of difficulties of obtaining enough acidic
132m from amyloid fibrils sufficient for biological analysis, acidic
f32m purified from the patients' urine that exhibited immuno-
chemical and physicochemical characteristics indistinguishable
from that in amyloid fibrils was used instead. It was demonstrated
that acidic J32m induces chemotaxis of monocytes and secretion of
potent bone-resorbing cytokines such as tumor necrosis factor-a
(TNF-a); interleukin-113 (IL-1p), and IL-6 from macrophages [15,
16]. These findings are in good agreement with previous histolog-
ical observations by others that amyloid deposits of long-term
hemodialysis patients with severe DRA were surrounded by a
number of monocytes/macrophages [17—19] immunochemically
stained positive for TNF-a and IL-1/3 [19].
Deamidation was detected previously in acidic f32m obtained
from the serum and amyloid deposits of hemodialysis patient with
DRA [20, 21]. As described above, we have shown that acidic 132m
contains Aniadori products and AGEs, demonstrating that acidic
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/32m is a mixture of heterogeneous molecular adducts derived
from various types of modification. Therefore, the nature of the
modification in acidic !32m that might contribute to the biological
activity toward monocytes/macrophages must be elucidated. In
the present study, we analyzed chemical structures of modification
in acidic 2m that was obtained from urine of long-term hemodi-
alysis patients. Furthermore, various isoforms of f32m prepared in
vitro exhibiting physicochemical characteristics indistinguishable
from those present in acidic J32m were used to assess their
biological functions, because of the difficulty of separating each
isoform of 2m present in acidic /32m. The results indicate that
AGEs, presumably other than pentosidine, are responsible for
monocyte chemotaxis and macrophage secretion of cytokines,
implicating a possible involvement of AGEs in the bone and joint
destruction in DRA.
Methods
Purification of normal and acidic 132m
Normal and acidic isoforms of /32m were purified from urine of
two non-diabetic hemodialysis patients who were free of urinary
infection (56-year-old male undergoing hemodialysis for 8 years
and 44-year-old female undergoing hemodialysis for 5 years) as
described previously [6]. These patients had been on regular
hemodialysis using a cuprophane dialyzer and a dialysate contain-
ing 30 mEq/liter bicarbonate and 8 mEq/liter acetate. Soon after
the urine samples were collected, they were dialyzed against
distilled water and used for purification. All reagents and buffers
were free of glucose, and care was taken to avoid contamination
with glucose during the purification procedure. The acidic f32m,
but not normal f32m, showed immunoreactivity to anti-AGE
antibody [22] as well as anti-Amadori product antibody [6].
For reduction of Amadori products [N-(1-deoxyfructosyl)
derivatives] in acidic f32m into N-(1-deoxyhexitolyl) derivatives,
acidic 132m (200 Lg) was treated with 5 mM sodium borohydride
(NaBH4; Nakalai Tesque, Kyoto, Japan) in 1 ml of 0.2 M
phosphate buffer (pH 8.5) at room temperature for four hours,
dialyzed against 50 m acetic acid to destroy excess NaBH4, and
then dialyzed against phosphate-buffered saline (pH 7.4).
In vitro preparation of Maillard-/32m, deamidated 132m,
fragmented /32m, and pentosidine-f32m
To prepare f32m modified with Maillard products (Maillard-
132m), normal 132m (500 gig) was incubated at 37°C for 10 days
(132m modified with Amadori products: Amadori-f32m) and 60
days (132m modified with AGEs: AGE-132m) with 100 ms'i D-
glucose (Wako Pure Chemicals, Osaka, Japan) in 500 tl of 100
m phosphate buffer (pH 7.4) containing 1.5 mivi phenylmethane-
sulfonyl fluoride (PMSF; Sigma) under sterile conditions. In some
experiments, f32m modified with reduced Amadori products (re-
duced Amadori-f32m) was prepared by incubating normal 2m
with glucose for 10 days in the presence of 40 m sodium
cyanoborohydride (NaBH3CN; Aldrich, Milwaukee, WI, USA).
Deamidated /32m was prepared by incubating normal /32m (150
g) under atmospheric oxygen at 65°C for eight hours in 500 jkl of
50 mM Tris-HC1 buffer (pH 8.0). Deamidation at two susceptible
sites (Asn-17 and Asn-42, see Results) in this preparation was
confirmed by mass spectrometry.
To prepare fragmented p2m with lysine-specific cleavage, nor-
mal /32m (200 jkg) was cleaved into fragments with 10 g (2.8
AU/mg) of Endoproteinase Lys-C (Endo Lys-C) (Acromobacter
Protease I; Wako Pure Chemicals) in 100 1d of 50 J.LM Tris-HCI
buffer (pH 9.0) at 37°C for eight hours. This mixture was then
ultrafiltered through a filter with a cut-off value of a molecular
weight of more than 10,000 (Ultrafree C3-LGC; Nihon Millipore
Ltd., Tokyo, Japan) to remove Endo Lys-C.
To prepare pentosidine-modified f32m or bovine serum albumin
(pentosidine-f32m or -BSA), pentosidine prepared by the method
of Grandhee and Monnier [23] was conjugated with normal J32m
or BSA. Briefly, 700 tg of protein was incubated with 1.5 i.tmol of
pentosidine and 0.01 mmol of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (Pierce, Rockford, IL, USA) in the
presence of 0.14 mg of N-hydroxysulfosuccinimide (Pierce)
in I ml of phosphate buffered saline for four hours at room
temperature, and then overnight at 4°C. Pentosidine incorporated
into these preparations was determined by high-performance
liquid chromatographic (HPLC) assay [24] using synthesized
pentosidine as a standard.
Mass spectrometly (MS)
An JMS SX1O2A instrument (JEOL, Akishima, Japan) was
used as described previously [9j. For electrospray ionization
(ESI)-MS, the source accelerating voltage was 7 kV. Samples were
dissolved in a solvent of 49/49/2 methanol/H2O/acetic acid (vol/
vol/vol) at a protein concentration of 10 pmol/ml. An aliquot (20
pA) of the sample solution was introduced into the ESI ion source
at a flow-rate of 0.8 i.d/min with a syringe pump (Harvard
Apparatus Model 22; Woburn, MA, USA). Fast atom bombard-
ment (FAB) ionization mode was employed for analysis of the
peptides digested with Endo Lys-C followed by purification by
HPLC (model LC-IOA; Shimadzu, Kyoto, Japan) on a C18
reverse-phase column (Nakalai Tesque). The FAB gun was
operated at a 30 mA current and 3 kV energy, using xenon as a
bombarding gas. The source accelerating voltage was 10 kV.
Approximately 100 jg of sample was dissolved in 10 pA of glycerol
as the sample matrix.
Capillaiy electrophoresis
Capillary zone electrophoresis was performed using a Quanta
4000CE system (Waters, Tokyo, Japan). The capillary cartridge
used was a 60 cm by 75 m cartridge (Waters). The peptides were
dissolved in 50 ,&LM sodium phosphate buffer (pH 2.5). The
capillary electrophoresis was run at 12 kV, and peptide elution
was monitored at 214 nm.
Assay for the Amadori product
The Amadori product was determined by the colorimetric assay
using a kit (Fructosamine Test Roche-Il; Nihon Roche Ltd.,
Tokyo, Japan) according to the manufacturer's instruction. The
assay is based upon the property of N-(1-deoxyfructosyl) group to
act as a reducing agent in alkaline solution. Poly-L-lysine was used
as a standard and the amount of Amadori products in each sample
was expressed as mol of N°-(1-deoxyfructosyl)-lysine per 1 mol of
132m. The limit of detection was 0.05 mol of N-(1-deoxyfructosyl)-
lysine/mol of f32m.
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Fluorospectrometty
Protein-bound fluorescence was analyzed in a fluorescence
spectrophotometer (model RF540; Shimadzu) at a protein con-
centration of 0.2 mglml in 10 m sodium phosphate buffer (pH
7.2).
Chemotaxis assay
For this experiment, we carefully removed endotoxins from the
materials using an endotoxin-adsorbent (Pyro Sep®; Daicel
Chemical Industries, Ltd., Tokyo, Japan) as described previously
[151. The monocyte chemotactic activity was assessed by a modi-
fication of the Boyden chamber technique in 24-well double
chambers separated by a filter (5 im pore size; Coster Corp.,
Cambridge, MA, USA) according to our previously reported
method [15]. Briefly, a human mononuclear leukocyte suspension
(6 x io cells) in 0.1 ml of Hanks' balanced salt solution (HBSS)
was added to the top compartment of the chamber, and the test
material in HBSS was added to the bottom compartment (0.6 ml).
The chamber was incubated at 37°C for four hours, and the filter
was then removed, fixed in methanol, and stained with Giemsa.
N-formylmethionylleucylphenylalanine (FMLP; Peninsula Labo-
ratories, Belmont, CA, USA), a synthetic peptide highly chemo-
tactic for monocytes, served as a positive control. Chemotactic
activity was defined as the average number of cells that had
migrated in response to test substance. The number of cells in
four high-power fields (X 400) was counted for each of the
triplicate chemotaxis chamber filters. The experiment was re-
peated three times utilizing mononuclear leukocyte preparations
from three healthy males (age range 28 to 33 years old).
Cytokine assay
Cytokine production by monocyte-derived macrophages was
determined by our previously reported method [15]. This experi-
ment was also performed using endotoxin-free materials. Mono-
cytes (2.5 x iO cells) in 0.5 ml of Dulbecco's modified Eagle's
medium (Nacalai Tesque) were incubated with 50 U interferon-y
(IFN-y; Shionogi Pharmaceutical Co., Osaka, Japan) and test
material in triplicate at 37°C for 24 hours. INF-y was added to
transform peripheral monocytes into the equivalent of primed
tissue macrophages [131. E. coli 0113:B4 endotoxin (DIFCO, Detroit,
MI, USA) was used as a positive control. After incubation in a
48-well culture plate (Sumilon; Sumitomo Bakelite Co. Ltd., Tokyo,
Japan), the culture medium was transferred into sterile microfuge
tubes and centrifuged at 400 >< g for five minutes to remove cells.
The cytokine level was then measured in duplicate in each superna-
tant with an ELISA kit for TNF-a, IL-113, or IL-6 according to the
manufacturer's instruction (Amersham, Buckinghamshire, UK).
Limits of detection were 16 pg/ml for TNF-a, 4 pglml for IL-1/3, and
3 pglml for IL-6. The experiment was repeated three times utilizing
monocyte preparations from three healthy males.
Statistical analysis
Data are expressed by mean SD. Analysis of variance
(ANOVA) was used for a statistical evaluation of significant
variations. If a significant variation was indicated by the analysis,
Scheffe's I-test was used to compare the values between different
concentrations of the same modification of 132m, or between
normal f32m and j32m with modification.
Fig. 2. Presence of deamidation in acidic 132m. A. Identification of the deamidation at Asn-17 and Asn-42 in acidic 2m by FAB-MS. Either normal f32m,
acidic /32m, or deamidated 2m was digested with Endo Lys-C and peptides were purified by HPLC on a C18 reverse-phase column. Molecular ion
regions for protonated peptides 2 (sequence 7 to 19: a-d) and 4 (sequence 42 to 48: e-h) are presented. Molecular masses for peptides 2 and 4 from
normal 132m are 1497.8 Da and 844.4 Da, respectively, and the mass spectra typically represent their isotopic distributions (a and e). The Asp-containing
peptides are larger than those containing Asn by one mass unit (c and g for synthesized peptides). Isotopic distributions of the peptides from acidic f32m
(b and f) and deamidated f32m (d and h) indicate partial deamidation in these peptides. B. Capillary electrophoresis of peptides 2 (a-c) and 4 (d-t).
IsoAsp-containing peptides (arrows) are eluted after those containing Asp. IsoAsp is the major product of deamidation in either peptide. a and d,
peptides from normal j32m; b and e, peptides from acidic f32m; c and f, synthesized peptides containing Asp instead of Asn.
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Fig. 3. Presence of Maillard products in acidic
132m. A. Detection of Amadori products in
normal /32m, acidic /32m, and Maillard-J32m.
Amadori products in these materials were
determined with the colorimetric method.
Incubation for Maillard-132m was carried out in
vitro with 0.1 M glucose or 0.4 M glucose (*) in
0.1 M phosphate buffer (pH 7.4) for the
incubation period (days) shown in parentheses.
Reduced Amadori-132m was prepared by
incubating normal 132m with glucose in the
presence of NaBH3CN (Maillard-132m +
NaBH3CN). ND, Not detected. B. Protein-
bound fluorescence for AGEs in normal 32m
(line 1), acidic 132m (line 2), deamidated /32m
(line 3), Maillard-132m after a 10 day incubation(Amadori-132m; line 4), a 60 day incubation
(AGE 32m; line 5), and a 10 day incubation in
the presence NaBH3CN (reduced Amadori-
132m; line 6). The emission fluorescence spectra
upon excitation at 350 nm (left) and the
excitation spectra for emission at 450 nm (right)
were measured at a protein concentration of 0.2
mg/mI.
Results
Presence of heterogeneous molecular adducts in acidic f32m
The molecular mass of 2m was analyzed by ESI-MS. Normal
2m was identified as a single major peak (peak N in Fig. 1A) with
a molecular mass of 11729.1 0.1 Da, in good agreement with the
theoretical value (11729.18 Da for chemical mass). A minor
component (peak n) with a molecular mass of 11745 Da was also
identified as the /32m oxidized at the carboxyl terminal methionine
residue. In the molecular mass analysis, acidic f32m showed two
features different from normal species (Fig. IB). First, the molec-
ular mass for the major peak (peak DE) was larger than that of
normal f32m by about one mass unit. This peak was ascribed to the
132m with deamidation as demonstrated by FAB-MS and capillary
electrophoresis of peptides as follows. Among eight peptides
isolated from an Endo Lys-C digest of acidic 132m on reverse-
phase HPLC, only fractions corresponding to peptide 2 (sequence
7 to 19) and peptide 4 (sequence 42 to 48) showed aberrant
isotopic distributions, obviously indicating partial deamidation of
asparagine residues (Asn-17 and Asn-42; Fig. 2A). Deamidation
of 132m has been reported or suggested at Asn-17 [20] and Asn-42
[211. At both sites, Asn is followed by Gly and thus must be very
susceptible for deamidation [25—27]. Since the deamidation of
Asn residues forms isoAsp:Asp peptide in a ratio of about 3:1 and
the resulting isoAsp products are resistant to Edman degradation
[26—28], we carried out capillary electrophoresis and confirmed
deamidation at these sites (Fig. 2B).
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The second remarkable feature of acidic f32m in Figure lB was
the presence of very heterogeneous molecules with masses rang-
ing from —100 to + 400 Da around the major component. Among
these heterogeneous components, a distinct peak was identified at
11891 Da (peak AM in Fig. 1B). The difference of 162 Da from
the normal !32m indicated that this component was the f32m with
one Amadori product. Since NaBH4 can reduce Amadori product
into N-(1-deoxyhexitolyl) derivative, we first treated acidic 132m
with NaBH4 and then analyzed this by ESI-MS. As expected, a
new peak with an adduct of 164 Da, corresponding to N-(1-
deoxyhexitolyl) group, was detected instead of 162 Da in the ESI
mass spectrum (data not shown). The presence of Amadori
product in acidic /32m was also confirmed by colorimetric method
(Fig. 3A): acidic f32m contained Amadori products (0.14 0.04
mol/mol of 132m), whereas Amadori product was virtually unde-
tectable in normal 132m. Our previous studies demonstrating
positive immunoreactivity of acidic 132m but not normal f32m to
anti-Amadori product antibody [6], and intense radioactive incor-
poration of sodium borotritide into acidic 2m but not into
normal /32m [91, further support that acidic f32m contained
Amadori products. By combination of peptide sequencing and
FAB-MS of Endo Lys-C-digested peptides from acidic f32m, we
recently identified the primary site of Amadori product in acidic
132m at the a-amino group of the amino terminal isoleucine and
the minor sites at the €-amino groups of six lysines [9]. These
findings, taken together, indicate that the native structures of the
major and minor Amadori products in acidic f32m are
deoxyfructosyl)-isoleucine and N-(1-deoxyfructosyl)-lysine, re-
spectively.
The present study provides an estimation of the extent of the
Maillard modification in acidic f32m. Based on the ESI mass
spectrum of acidic f32m (Fig. 1B) and the result of colorimetric
assay (Fig. 3A), Amadori products accounted for about 10% of
the acidic 132m preparation. This is in good agreement with our
recent observation that the radioactive incorporation of sodium
borotritide, which reduced Amadori products, was about 15% of
acidic f32m [9]. The proportion of AGEs in acidic 2m could be
less than 1%. However, precise determination was impossible
because they did not show distinct peaks on ESI-MS. Since
Maillard products contain both Amadori products and AGEs, the
A
DE de
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B
Fig. 4. Representative transfonned ESI mass
spectra of deamidated j32m (A) and Maillard-!32m
upon incubation for 10 days (Amadori-132m; B),
60 days (AGE-132m; C), and /0 days in the
presence of NaBH3CIV freduced Amadori-132m;
B). Abbreviations are: DE, 32m with
deamidation; AMX, f32m with Amadori
products (X indicates the number of Amadori
products contained); AM'X, 132m with reduced
Amadori products (X indicates the number of
reduced Amadori products contained). f32m
oxidized at the carboxyl terminal methionine
residue is shown by the lower cases. The
molecular masses are 11730 Da (peak DE),
11891 Da (peaks AM1), 12053 Da (peak AM2),
12215 Da (peak AM3), 12377 Da (peak AM4),
11893 Da (peak AM'l), 12057 Da (peak
AM'2), 12221 Da (peak AM'3), and 12385 Da
(peak AM'4).
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Fig. 5. Comparison of monocyte chemotactic
activity between normal and acidic I3?m (A), and
among normal /32m and !32m with heterogeneous
modifications consisting of acidic 132m (B).
Monocyte chemotaxis was examined by a
modified Boyden chamber technique with
normal and acidic 32m, using FMLP at 10 ng/
ml as a positive control and medium itself as a
negative control, or with normal fi2m,
deaminated J32m, and Maillard-f32m upon
incubation for 10 days (Amadori-/32m) and 60
days (AGE J32m). ESI mass spectra of these in
vitro preparations are shown in Figure 4.
Representative data from the three experiments
are shown. Data are expressed as means SD.
N = 3. < 0.05 and P < 0.001 versus
normal 2m. §P < 0.001 between those of
different concentrations of the same
modification of f32m.
latter being a minor constituent, Maillard products may be at most
about 10% of acidic f32m. A large fraction (more than 80%) of
acidic 132m is deamidated as shown above. Our purification
procedure of acidic f32m, depending upon the electrophoretic
mobility on ion exchange chromatography, cannot efficiently
separate deamidated /32m from those modified with Maillard
products, because both of these modifications result in a potent
electrophoretic shift to an acidic position.
In vitro preparation of heterogeneous molecular adducts present in
acidic 2m
To investigate the modification responsible for the biological
activity of acidic 2m such as chemotaxis of monocytes and
secretion of cytokines from macrophages, f32m with heteroge-
neous modification present in acidic j32m was prepared in vitro.
Since deamidation has been reported to be generated easily at
Asn-Gly sequences in proteins in vitro [25—28], we prepared 2m
with deamidation by incubating normal 2m at 65°C for eight
hours. Maillard-J32m was prepared by incubating normal /32m with
glucose. Apparently, Maillard-132m after a long-period incubation
(60 days) turned a brown color like acidic f32m, but both deami-
dated 2m and Maillard-2m after a short-period of incubation
(10 days) were colorless like normal /32m. When these materials
were subjected to two-dimensional PAGE, a major portion of all
the materials was electrophoresed to a position similar to that of
acidic 132m (data not shown). Of particular interest was the
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Fig. 6. Comparison of cytokine inducing activity
from human macrophages between normal and
acidic f32m. Monocytes were incubated for 24
hours at 37°C in medium containing human
INF-y (50 units) in the presence of test
substance, using B4 endotoxin from E. coli at 5
ng/ml as a positive control and medium
containing TNF-y as a negative control,
followed by determination of TNF-cs (A), IL-1J3(B), and IL-6 (C) levels in culture media
by ELISAs. Representative data from the three
experiments are shown. Data are expressed as
means SD. N = 3. < 0.0001 versus normal
132m. P < 0.0001 between those of different
concentrations of the same modification of
132m.
striking polymerization of Maillard-132m after a long-period incu-
bation on electrophoresis (data not shown). No such tendency for
polymerization of /32m was observed in deamidated f32m or
Maillard-j32m upon incubation in the presence of NaBH3CN,
which reduces Schiff base, prevents Amadori rearrangement, and
inhibits formation of cross linking. When the protein-bound
fluorescence was examined (Fig. 3B), Maillard-2m after a long-
period incubation (line 5) fluoresced markedly with almost the
same fluorescence spectra with acidic 132m (line 2). On the other
hand, neither normal 2m (line 1), deamidated J32m (line 3), nor
Maillard-/32m after a short-period incubation (line 4) fluoresced
at all. Hence, the characteristic triad of AGE-proteins [7, 8],
namely, the brown color, fluorescence, and polymerization ten-
dency, was recognized with both Maillard-/32m after a long-period
incubation and acidic 2m, but not with normal 2m, deamidated
32m, nor Maillard-2m after a short period of incubation.
ESI-MS of deamidated 132m (Fig. 4A) gave a mixture of the
132m with deamidation (peak DE) and its oxidized form (peak de),
and FAB-MS of Endo Lys-C-digested peptides from deamidated
/32m (Fig. 2A, d and h) revealed the presence of deamidation at
Asn-17 and Asn-42 in about 90% of this preparation. ESI-MS of
Maillard-f32m upon incubation for 10 days (Fig. 4B) gave several
major peaks for Amadori products (AM1-AM3 and aml-am2) in
addition to the /32m with deamidation (DE and de). The presence
of Amadori products in this preparation was also confirmed by
measuring Amadori products with colorimetric assay (Fig. 3A).
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Fig. 7. Comparison of cytokine inducing activity
from macrophages among normal J32m, 13,m with
heterogeneous modifications consisting of acidic
132m, and fragmented 132m. Deamidated f32m,
Maillard-p2m upon incubation for 10 days
(Amadori-132m) or 60 days (AGE-J32m), or
fragmented /32m was prepared in vitro and
incubated with monocytes for determination of
its cytokine inducing activity. A. TNF-a. B. IL-
1. C. IL-6. Representative data from the three
experiments are shown. Data are expressed as
means SD. N = 3. *p < 0.0001 versus normal
132m. P < 0.0001 between those of different
concentrations of the same modification of
132m.
Maillard-2m upon incubation for 10 days contained a significant
amount of Amadori products (0.45 0.03 mol/mol of /32m)
compared to its absence in normal 2m. The transformed ESI
mass spectrum of Maillard-f32m upon incubation for 60 days (Fig.
4C) was similar to that of Maillard-2m upon incubation for 10
days, except for more intense peaks for Amadori products (aml-
am4) and the presence of very heterogeneous molecules in the
former. Note that Maillard-132m upon incubation for 60 days,
which possessed the same characteristic properties as the AGE-
modified protein, contained mostly Amadori products (0.69
0.02 mol/mol of 2m, Fig. 3A). The proportion of AGEs in
Maillard-132m upon incubation for 60 days could be very minor
(less than 1%), although precise determination was impossible
since ESI-MS did not show distinct peaks for AGEs. These
findings indicate that intense Maillard modification occurs even
after a shorter incubation period, but these are mainly Amadori
products, and that the pigmented and fluorescent adducts (AGEs)
are generated only after a longer incubation period.
AGEs are causal for the biological activity of acidic 132, n toward
monocytes/macrophages
When migration of peripheral human monocytes toward nor-
mal or acidic 132m was measured in modified Boyden chambers
(Fig. 5A), acidic f32m exhibited direct migratory activity in a
dose-dependent manner (P < 0.001), whereas normal f32m elic-
ited only a weak migratory activity of monocytes. Furthermore,
addition of acidic J32m resulted in a dose-dependent increase (P <
0.0001) in levels of cytokines such as TNF-a, IL-113, and IL-6 in
the culture medium, released from macrophages (Fig. 6). In
contrast, the medium of the cells incubated with normal f32m, even
at a high concentration, contained only a small amount of
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Acidic 32m 50 lgml
Acidic 2m + NaBH4 50 pg/mI
Reduced Amadori-132m 50 pg/mI
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Fig. 8. Comparison of cytokine inducing activity
from macrophages among normal f32m, acidic
J32m, acidic 132m treated with NaBH4 (acidic 132m
+ NaBH4), and reduced Amadori-f32m. Reduced
Amadori-j32m was prepared by incubating
normal j32m with glucose in vitro for 10 days in
the presence of NaBH3CN. A. TNF-a. B. IL-uI.
C. IL-6. Representative data from the three
experiments are shown. Data are expressed as
means SD. N = 3. P < 0.0001 versus normal
1321m
cytokines. Chemotactic and cytokine inducing activities of acidic
132m were much higher than those of normal /32m (P < 0.001 and
P < 0.0001, respectively), in good agreement with our previous
results [15, 161.
We then examined f32m with heterogeneous modification
present in acidic /32m together with normal 132m. The pigmented
and fluorescent AGE-132m exhibited direct migratory activity of
monocytes (Fig. 5B). However, deamidated /32m or Amadori-f32m
elicited only a weak migratory activity. The chemotactic activity of
AGE-/32m was significantly higher than that of normal /32m (P <
0.05), but there was no statistically significant difference between
deamidated J32m or Amadori-/32m, and normal f32m.
Furthermore, AGE-f32m remarkably increased TNF-cs, IL-I/I,
and IL-6 in a dose-dependent manner (P < 0.0001) in the culture
medium of macrophages (Fig. 7). On the other hand, deamidated
/32m or Amadori-/32m induced only a small increase of cytokines
even at a high concentration. The cytokine inducing activity of
AGE-/32m was remarkably higher than that of normal /32m (P <
0.0001), but there was no significant difference in the activity
between deamidated /32m or Amadori-/32m, and normal /32m.
The fragmented f32m induced only a small amount of cyto-
kine release from macrophages (Fig. 7), and there was no
significant difference in the activity between fragmented J32m
and normal f32m, implicating that fragmentation by itself is not
a modification responsible for the cytokine inducing activity
from macrophages.
Pretreatment of acidic /32m with NaBH4 that reduces Amadori
products into N-(1-deoxyhexitolyl) derivatives did not alter the
cytokine inducing activity of acidic /32m (Fig. 8). This finding,
together with the observation that N-(1-deoxyhexitolyl) deriva-
tives prepared in vitro (Fig. 4D) could induce only a small amount
of cytokine release from macrophages (Fig. 8), indicates that
Amadori products in acidic /32m do not contribute in a significant
manner to the cytokine inducing activity.
Synthesized pentosidine as well as in vitro-prepared pentosi-
dine-/32m and -BSA induced only a small amount of cytokine
release from macrophages (Fig. 9), and there was no significant
difference in the activity between pentosidine-132m and normal
,32m. Thus, it is likely that pentosidine is inert with respect to
cytokine inducing activity. However, because the chemical binding
of pentosidine to /32m obtained by the present preparative method
was quite different from the native one that involves a lysine and
an arginine residue combined in an imidazo-(4, 5b)-pyridinium
ring [10], the possibility remains that pentosidine-modified 32m in
the native form in vivo may exert a cytokine-inducing activity.
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Fig. 9. Cytokine inducing activity of pentosidine.
A. TNF-a. B. IL-113. C. IL-6. The pentosidine
levels in normal /32m, acidic /32m, and
pentosidine-/32m and -BSA were < 0.002 pmol/
mg, 0.144 pmol/mg, 21.0 pmol/mg, and 29.1
pmot/mg, respectively, as estimated by HPLC
assay [24]. Representative data from the three
experiments are shown. Data are expressed as
means SD. N = 3. < 0.0001 versus normal
132m.
Discussion
We hypothesized that AGEs formed nonenzymatically between
132m and sugar play a pathological role in DRA. This contention
was based on two recent findings. First, acidic /32m is a major
constituent of amyloid fibrils in DRA, and acidic f32m in the
serum, urine, and amyloid fibrils contains AGEs that have been
implicated in tissue damage associated with diabetic complica-
tions and aging [6]. Secondly, acidic 132m purified from urine of
long-term hemodialysis patients exhibits various biological activ-
ities toward monocytes/macrophages that are characteristic for
AGE-proteins [15, 16]. However, we found that acidic 132m is a
mixture of heterogeneous molecular adducts due to various types
of modification. Among these, AGEs are present in only a small
fraction of acidic f32m, as shown previously in serum proteins [24]
and skin collagen [291. Several previous studies have demon-
strated the biological effects of AGE-proteins on monocytes/
macrophages [12—14], prepared in vitro by incubating proteins
with glucose. However, these preparations also consisted of
heterogeneously modified proteins such as deamidation, Amadori
products and AGEs, among which AGEs are minor constituents.
To our knowledge, the biological activity of deamidation and
Amadori products has not been examined. Thus, we cannot simply
conclude that AGEs are the causal modification for chemotactic
activity and cytokine inducing activity of acidic f32m. To further
confirm our initial hypothesis, we analyzed the chemical modifi-
cations in acidic /32m purified from urine of long-term hemodial-
ysis patients and investigated the biological activity of each
modification. The results indicated that neither deamidated j32m
nor Amadori f32m, both of which were major modifications
present in acidic /32m, exhibited the biological activity. In contrast,
AGE-2m, although only a minor constituent in acidic f32m,
induced monocyte chemotaxis and macrophage secretion of po-
tent bone-resorbing cytokines such as TNF-a, IL-1, and IL-6.
These findings suggest that AGEs are responsible for the chemo-
tactic activity and the cytokine inducing activity of acidic 2m,
conferring a pathological significance to AGEs in bone and joint
destruction in DRA.
The present study revealed that deamidation occurred at the
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two Asn-Gly sequences in f32m via a succinimide intermediate
which breaks down by two pathways to yield a-aspartate (Asp)
and its p-isomer (isoAsp) in a ratio of about 1:3. A previous study
using a synthetic peptide demonstrated a rapid deamidation
reaction at Asn-Gly sequences with a half-life of only 1.4 days at
37°C, pH 7.4 [261, suggesting that Asn residues may be hot spots
for nonenzymatic degradation of most proteins and can limit their
biological lifetime. Thus, deamidation at Asn residues is not a
modification specifically occurring in /32m, but a generally occur-
ring reaction with a variety of proteins. Furthermore, as deami-
dation is a spontaneous degradation reaction occurring easily
under physiological conditions [28], some fraction of deamidated
2m in the acidic 132m preparation may be generated during the
purification procedure. As far as we have investigated, deami-
dated 2m exerts no biological activity towards monocytes/mac-
rophages.
In regard to the amyloid formation (amyloidogenesis) of 2m,
Linke et al demonstrated that proteases can cleave some lysine
residues of 2m, thus increasing its hydrophobic tendency and
contributing to amyloidogenesis [30]. Therefore, although frag-
mented 2m did not exhibit the biological activity, proteolytically
cleaved /32m might favor amyloid formation. Although some
researchers recently suggested the possible involvement of non-
enzymatic glycation in the amyloidogenesis of J3-amyloid peptide
in Alzheimer's disease [31, 32], the role of AGEs or Amadori
products in the amyloidogenesis of f32m is unclear.
The pathological role of pentosidine in DRA is an issue of
particular interest. Although our experiments concerning the
biological activity of pentosidine-modified /32m in the native form
in vivo are as yet inconclusive, the results thus far obtained suggest
that pentosidine is neutral with respect to cytokine induction in
macrophages. Previous studies have demonstrated that pentosi-
dine formation maybe involved in oxidative stress [11,23,331, and
that increased glycation promotes the formation of free radicals
and enhances oxidative damage in proteins and lipids [34]. It was
demonstrated that there is a close association between pentosi-
dine level and occurrence of diabetic complications [35—37].
Therefore, the oxidative stress associated with pentosidine forma-
tion in amyloid fibrils might be involved in the development of
bone and joint destruction of DRA.
Thus, precise structure of AGEs in acidic /32m responsible for
monocyte chemotaxis and cytokine induction from macrophages
remains unknown. It was demonstrated that neither 2-(2-furoyl)-4
(5)-(2-furanyl)-1H-imidazole (FF1) [38], pyrraline [39], nor their
BSA conjugates showed ligand activity for the AGE-receptor of
rat peritoneal macrophages [22, 40], suggesting these AGE-
structures may not be responsible for the biological activity toward
monocytes/macrophages. In accord with the current findings, the
chemical structure responsible for the biological activity may be
different from the AGE-structures postulated so far. Our previous
study [61 showed that acidic 2m reacted with anti-AGE antibody
[22]. However, the epitope is neither pentosidine, FF1, nor
pyrraline (unpublished data), indicating the presence of another
AGE-structure distinct from those postulated so far. A prelimi-
nary study by Makita et al [41] has also shown that neither
pentosidine, FF1, nor pyrraline cross react with their anti-AGE
antibody. At present, the structure of epitope of these anti-AGE
antibodies remains unknown, and we do even not know whether
or not this epitope really contributes to the biological activity
toward monocytes/macrophages. Taking into account the findings
of several reports concerning the biological effects of AGEs
toward monocytes/macrophages [12—16], endothelial cells [42],
and mesangial cells [43, 44], a further characterization of the
remaining AGE-structure(s) and its biological significance is
imperative to better understand the molecular mechanisms of the
pathophysiological role of AGEs in diabetic complications, aging,
and DRA.
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Appendix
Abbreviations used in this paper are: AGEs, advanced glycation end
products; 132m, /32-microglobulin; BSA, bovine serum albumin; Endo
Lys-C, Endoproteinase Lys-C; ESI, electrospray ionization; FAB, fast
atom bombardment; FF1, 2-(2-furoyl)-4-(5)-(2-furanyl)-1H-imidazole;
FMLP, N-formylmethionylleucylphenyl-alanine; DRA, dialysis-related
amyloidosis; HBSS, Hanks' balanced salt solution; HPLC, high-perfor-
mance liquid chromatography; IL-113, interleukin-l/3; IL-6, interleukin-6;
INF-y, interferon-y; MS, mass spectrometly; NaBH4, sodium borohydride;
NaBH3CN, sodium cyanoborohydride; TNF-a, tumor necrosis factor-a.
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